Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial ‘Tactical athletes’ get new guidance for cardiovascular fitness Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era An AI drug specialist zeroes in on rare forms of obesity GSK wagers up to $1.3B on a different kind of cancer drug TScan cuts 75% of workforce while shifting focus to solid tumor program RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer US to grant up to $125M for personalized RNA manufacturing innovation Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review Breaking borders: Building biotech scale in Benelux Biopharma needs more data scientists. Who’s getting hired? The top 12 companies hiring in biopharma now Capricor, Replimune illustrate why FDA must listen to rare disease specialists Why are drug overdose deaths declining? FDA raises bar for foreign site inspections as China trials surge Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts Replimune’s melanoma drug would have been rejected again if not for senior CBER official New Spectrometry Technique Could Aid Formulation Development UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division Partners explore T cell engaging approaches for solid tumours Follow the money: How funding announcements can help identify jobs before they’re posted UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails The physicochemical design, structure and permeability of the JCVI-syn3A minimal cell membrane Machine learning interprets genome sequences to map possible microbial symbionts STAT+: ADA review of members’ expulsion denies group censored opinions, called in police Opinion: Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples STAT+: House votes to temporarily block Trump plan to politicize federal grants Opinion: I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field Mid-cap biotechs join Trump’s latest round of drug pricing deals Roche finds another oncology gem in Asia with $1.5B B cell disease partnership GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T 9 midsize drugmakers climb aboard Trump’s MFN train Psilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice Why G‑quadruplex biology is back and what it means for MYC‑driven cancers A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns Home